Indivior to Announce Half Year 2017 Results on July 27th07.13.2017
Slough, UK, and Richmond, VA, 13 July 2017 – Indivior PLC (LON: INDV) today announced that it will release its half year 2017 results on July 27th at 7:00 a.m. London time (2:00 a.m. U.S. EDT). The results will be available via the London Stock Exchange’s Regulatory News Service (RNS) and on the “Investors” section of the company’s website at www.indivior.com.
Key members of Indivior’s leadership team led by Shaun Thaxter, Chief Executive Officer, will present the half year 2017 results and address questions from qualified analysts and investors at 12 noon London time (7:00 a.m. U.S. EDT) on the same day (July 27th). The presentation will take place at The Ayres Room, Deutsche Bank, Winchester House, 75 London Wall, London EC2N 2DB.
If you plan to attend the presentation in person please RSVP to Jason Thompson, Vice President, Investor Relations, at email@example.com.
Access the Live Webcast for Indivior’s Half Year 2017 Results Presentation
A live webcast of the half year 2017 results presentation also will take place. The webcast event and materials will be available on the “Investors” section of the company’s website at www.indivior.com shortly before the event begins on July 27th at noon London time (7:00 a.m. U.S. EDT). The webcast link is http://edge.media-server.com/m/p/3hzfgb5o. Participants also may access the half year 2017 results telephonically: US participants 1-646-254-3365; international participants 44(0)20-3427-1916. Please reference confirmation number 5143659. A replay of the presentation will be available at www.indivior.com.
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline “Focus on you” makes the Company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.
Vice President, Investor Relations
Tel: 804-423-8916 or firstname.lastname@example.org